Impact of an Intermediate Respiratory Care Unit on Clinical Outcomes of COVID-19 Patients

Guillermo Suarez-Cuartin ([email]gsuarezc@bellvitgehospital.cat)  
Hospital Universitari de Bellvitge  https://orcid.org/0000-0003-2320-6047

Merce Gasa  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Guadalupe Bermudo  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Yolanda Ruiz-Albert  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Marta Hernandez-Argudo  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Alfredo Marin  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Pere Trias-Sabria  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Ana Cordoba  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Albert Ariza  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Joan Sabater  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Nuria Romero  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Cristina Subirana  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Maria Molina-Molina  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Salud Santos  
Bellvitge University Hospital: Hospital Universitari de Bellvitge

Research

Keywords: COVID-19, Pneumonia, IMCU, ICU, NIV, HFNC
Abstract

Background: Many severe COVID-19 patients require respiratory support and monitoring. An intermediate respiratory care unit (IMCU) may be a valuable element for optimizing patient care and limited health-care resources management. We aim to assess the impact of an IMCU in the management of severe COVID-19.

Methods: Observational, retrospective study including patients admitted to the IMCU due to COVID-19 pneumonia during the months of March and April 2020. Patients were stratified based on their requirement of transfer to the intensive care unit (ICU) and on survival status at the end of follow-up. A multivariable Cox proportional hazards method was used to assess risk factors associated with mortality.

Results: A total of 253 patients were included. Of them, 68% were male and median age was 65 years (IQR 18 years). Ninety-two patients (36.4%) required ICU transfer. Patients transferred to the ICU had a higher mortality rate (44.6% Vs 24.2%; p<0.001). Multivariable proportional hazards model showed that age ≥65 years (HR 4.14; 95%CI 2.31-7.42; p<0.001); chronic respiratory conditions (HR 2.34; 95%CI 1.38-3.99; p=0.002) and chronic kidney disease (HR 2.96; 95%CI 1.61-5.43; p<0.001) were independently associated with mortality. High-dose systemic corticosteroids followed by progressive dose tapering showed a lower risk of death (HR 0.15; 95%CI 0.06-0.40; p<0.001).

Conclusions: IMCU allow to safely and effectively manage severe COVID-19 patients requiring respiratory support and non-invasive monitoring, therefore reducing ICU burden. Older age and chronic respiratory or renal conditions are associated with worse clinical outcomes, while treatment with systemic corticosteroids may have a protective effect on mortality.

Background

Coronavirus disease 2019 (COVID-19) is a respiratory condition caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) (1). Patients with COVID-19 may become severely ill and require hospital admission, with estimated hospitalization rates of 1–18%, depending on age group (2). Current recommendations state that patients with COVID-19 related acute respiratory failure should be monitored, and support with high-flow nasal cannula (HFNC) oxygen therapy or non-invasive ventilation (NIV) should be considered when conventional oxygen therapy fails (3). In this regard, during the months of March and April of 2020, the COVID-19 pandemic conditioned a significant increase in healthcare burden across Europe, as 17–32% of admitted patients required critical care management (4–7). The intensive care unit (ICU) beds and invasive mechanical ventilators achieved their limits of occupation, hence non-invasive supportive care was a valuable option for maintaining respiratory conditions. Therefore, a proper healthcare resource management was necessary to warrant an adequate patient care.

Intermediate respiratory care units (IMCU) are a useful resource for the management of complex patients that do not require admission to the ICU, invasive mechanical ventilation or invasive monitoring (8). IMCU can function as a space for management escalation and de-escalation between the general ward and the
ICU, especially when patient monitoring is needed and/or when respiratory support with HFNC or NIV is required (8–10). Benefits of IMCU include reducing ICU admission time and increasing ICU bed capacity, as well as lowering mortality and health care costs (8, 10, 11). Although it is well known the importance of ICU, the impact and specific role of IMCU during the COVID-19 pandemic has not been properly assessed.

To this date, there have been more than 20 million reported cases worldwide, with over 730 thousand deaths (12). Mortality is variable among hospitalized patients with COVID-19 pneumonia. Studies from Chinese cohorts estimate a hospital mortality of 4–28% (4, 5, 13). Furthermore, a recent study from the United Kingdom showed an overall mortality of 26% in admitted patients (7). Most of these deaths were related to sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and heart failure (4). Moreover, mortality rates of patients in critical care are higher, ranging from 26–32% (7, 14), including ICU and IMCU. Nevertheless, the specific mortality of COVID-19 patients admitted to an IMCU has not been widely studied.

We aim to evaluate the impact of IMCU management on clinical outcomes of severely ill COVID-19 patients requiring monitoring and/or non-invasive respiratory support.

**Methods**

**Study design**

An observational and retrospective study was performed on consecutive patients admitted to the IMCU of a tertiary care hospital in Barcelona (Spain) throughout the months of March and April 2020. The final date of follow-up was June 28, 2020. Study protocol was approved by the local ethics committee (Nº PR260/20). Inclusion criterion was admission to IMCU due to respiratory failure related to COVID-19 pneumonia requiring non-invasive monitoring and/or non-invasive respiratory support. Patients were diagnosed with a positive polymerase chain reaction for SARS-CoV2 from nasopharyngeal swab and the presence of patchy infiltrates on chest X-ray. According to local protocol, IMCU admission was limited to subjects with an oxygen saturation (SpO2) to inspired oxygen fraction (FiO2) ratio lower than 200 but not expected to require immediate support with invasive mechanical ventilation. Exclusion criteria were: recent admission to the ICU and respiratory failure due to any etiology other than COVID-19.

**Data collection and analysis**

Demographic, clinical, radiological and laboratory data were collected from electronic medical records for all patients at the time of IMCU admission. All participants were treated according to hospital protocols. Systemic corticosteroid therapy was divided into three categories depending on dose and administration route, as patients were treated before preliminary results from the RECOVERY trial (15): intravenous (IV) bolus of 1–2 mg/Kg/day methylprednisolone or its equivalent dexamethasone dose for 3 days, followed or not by oral prednisone starting from 0.5 mg/Kg/day, tapering the dose over 7 to 10 days. Treatment schemes were chosen depending on clinical and radiological severity, where more severe individuals
received longer treatments. Patients were categorized depending on survival status and ICU transfer requirement during hospitalization. ICU admission criteria included cardiopulmonary arrest, sudden fall in level of consciousness, invasive ventilation requirement and shock. The decision of whether or not to transfer a patient to the ICU was always made by a multidisciplinary team including pulmonologists and intensive care physicians. For the survival analysis, clinical and laboratory features were studied using criteria for ARDS (16) and cut-off values identified in severe cases from previous studies (4, 5, 17–19).

**Statistical analysis**

Frequency and percentages were used to present categorical data, and chi-squared test or Fisher’s exact test were used to evaluate their differences. Continuous variables are expressed as mean and standard deviation (SD) for normally distributed variables or median and interquartile range (IQR) otherwise. ANOVA and Student’s t test or their corresponding non-parametrical tests were used to evaluate their differences, when required. Kaplan-Meier curves were used for the survival analysis. In order to identify factors associated with mortality, a multivariable Cox proportional hazards analysis was performed including significant variables from univariate analysis. A p-value < 0.05 was considered statistically significant. Data were analyzed using R (software version 3.6.2).

**Results**

**Patient description**

A total of 291 patients were admitted to the IMCU during the months of March and April of 2020 due to COVID-19 pneumonia. After excluding 38 patients that were previously treated in the ICU, 253 patients were finally included. Of them, 68% were male and median age was 65 years (IQR 18 years). The most frequent comorbidities were hypertension (50.2%), dyslipidemia (47.8%) and diabetes mellitus (29.6%). Demographic and clinical characteristics of included patients at admission to IMCU are described in Table 1.
Table 1
Characteristics of all patients admitted to the respiratory intermediate care unit, and according to requirement of transfer to the ICU

|                                                | Total (N = 253) | No ICU admission (N = 161) | ICU admission (N = 92) | p-value |
|------------------------------------------------|-----------------|-----------------------------|------------------------|---------|
| Male, n (%)                                    | 172 (67.9%)     | 104 (64.6%)                 | 68 (73.9%)             | 0.165   |
| Age in years, median (IQR)                     | 65 (18)         | 66 (19)                     | 63 (15.3)              | 0.072   |
| **Comorbidities**                              |                 |                             |                        |         |
| Hypertension, n (%)                            | 127 (50.2%)     | 85 (52.8%)                  | 42 (45.7%)             | 0.336   |
| Diabetes, n (%)                                | 75 (29.6%)      | 44 (27.3%)                  | 31 (33.7%)             | 0.356   |
| Dyslipidemia, n (%)                            | 121 (47.8%)     | 75 (46.6%)                  | 46 (50%)               | 0.695   |
| Obesity, n (%)                                 | 63 (24.9%)      | 40 (24.9%)                  | 23 (25%)               | >0.999  |
| Cardiovascular disease, n (%)                  | 27 (10.7%)      | 19 (11.8%)                  | 8 (8.7%)               | 0.577   |
| **Chronic respiratory disease, n (%)**         |                 |                             |                        |         |
| Asthma                                         | 14 (5.5%)       | 8 (4.9%)                    | 6 (6.5%)               | 0.789   |
| COPD                                           | 17 (6.7%)       | 13 (8.1%)                   | 4 (4.3%)               |         |
| Interstitial lung disease                      | 6 (2.4%)        | 3 (1.9%)                    | 3 (3.3%)               |         |
| Bronchiectasis                                 | 1 (0.4%)        | 1 (0.6%)                    | 0                      |         |
| OSAS                                           | 15 (5.9%)       | 9 (5.6%)                    | 6 (6.5%)               |         |
| History of malignancy, n (%)                   | 37 (14.6%)      | 24 (14.9%)                  | 13 (14.1%)             | >0.999  |
| Chronic liver disease, n (%)                   | 22 (8.7%)       | 18 (11.2%)                  | 4 (4.4%)               | 0.105   |
| Chronic kidney disease, n (%)                  | 27 (10.7%)      | 19 (11.8%)                  | 8 (8.7%)               | 0.577   |
| Immunosuppression, n (%)                       | 13 (5.1%)       | 10 (6.2%)                   | 3 (3.3%)               | 0.386   |
| **Symptoms**                                   |                 |                             |                        |         |
| Dyspnea, n (%)                                 | 149 (58.9%)     | 86 (53.4%)                  | 63 (68.5%)             | 0.027*  |
| Cough, n (%)                                   | 189 (74.7%)     | 117 (72.7%)                 | 72 (78.3%)             | 0.405   |
| Fever, n (%)                                   | 211 (83.4%)     | 131 (81.4%)                 | 80 (86.9%)             | 0.330   |
| Myalgias, n (%)                                | 71 (28.1%)      | 49 (30.4%)                  | 22 (23.9%)             | 0.334   |

ICU: Intensive care unit; IQR: Interquartile range; COPD: Chronic obstructive pulmonary disease; OSAS: Obstructive sleep apnea syndrome; SpO2: Oxygen saturation; FiO2: Fraction of inspired oxygen; IMCU: Intermediate care unit
|                                | Total (N = 253) | No ICU admission (N = 161) | ICU admission (N = 92) | p-value |
|--------------------------------|-----------------|----------------------------|------------------------|---------|
| **Diarrhea, n (%)**           |                 |                            |                        |         |
|                                | 64 (25.3%)      | 38 (23.6%)                 | 26 (28.3%)             | 0.503   |
| **Nausea, n (%)**             |                 |                            |                        |         |
|                                | 22 (8.7%)       | 12 (7.5%)                  | 10 (10.9%)             | 0.487   |
| **Days from symptom onset to** |                 |                            |                        |         |
| hospital admission (median IQR)| 8 (5)           | 8 (5)                      | 8 (5)                  | 0.821   |
| **Days from symptom onset to** |                 |                            |                        |         |
| IMCU admission (median IQR)    | 10 (7)          | 10 (7)                     | 9 (7.3)                | 0.176   |

**Chest X-ray on admission**

|                                |                 |                            |                        |         |
|                                | 149 (58.9%)     | 143 (90.5%)                | 89 (96.7%)             | 0.113   |
| **Peripheral distribution of opacities, n (%)** | 189 (74.7%)     | 96 (60.8%)                 | 48 (52.2%)             | 0.233   |

**Laboratory blood tests**

|                                |                 |                            |                        |         |
|                                | 8.60 (5.6)      | 7.80 (4.8)                 | 10.15 (6.5)            | <0.001* |
| **Lymphocyte count (x10^9/L), median (IQR)** | 0.68 (0.6)      | 0.73 (0.6)                 | 0.64 (0.6)             | 0.039*  |
| **Lactate dehydrogenase (U/L), median (IQR)** | 418 (221)       | 398 (220.5)                | 446 (237)              | 0.005*  |
| **C-Reactive protein (mg/L), median (IQR)** | 137 (177)       | 108 (148)                  | 179.50 (188)           | <0.001* |
| **Ferritin (µg/L), median (IQR)**              | 1443 (1337)     | 1479 (1426)                | 1410 (1242.8)          | 0.829   |
| **D-dimer (µg/L), median (IQR)**               | 531 (814.3)     | 506.50 (821.3)             | 599.50 (757.5)         | 0.446   |

**Treatment**

|                                |                 |                            |                        |         |
|                                | 202 (79.8%)     | 126 (78.3%)                | 76 (82.6%)             | 0.505   |
| **Remdesivir, n (%)**          |                 |                            |                        |         |
|                                | 11 (4.4%)       | 2 (1.2%)                   | 9 (9.8%)               | 0.004*  |
| **Hydroxychloroquine, n (%)**  |                 |                            |                        |         |
|                                | 243 (96.1%)     | 151 (93.8%)                | 92 (100%)              | 0.035*  |
| **Tocilizumab, n (%)**         |                 |                            |                        |         |
|                                | 124 (49%)       | 73 (45.3%)                 | 51 (55.4%)             | 0.157   |

ICU: Intensive care unit; IQR: Interquartile range; COPD: Chronic obstructive pulmonary disease; OSAS: Obstructive sleep apnea syndrome; SpO2: Oxygen saturation; FiO2: Fraction of inspired oxygen; IMCU: Intermediate care unit
Clinical outcomes

Ninety-two patients (36.4%) required transfer to the ICU. There were no significant differences in age, gender or comorbidities between ICU and non-ICU groups. However, patients requiring ICU management had higher systemic inflammatory markers and a significant lower SpO2/FiO2 ratio on admission. A comparison of patient characteristics between those that were admitted to the ICU and those who did not, is shown in Table 1.

A higher proportion of patients received home discharge in the IMCU group compared to those that required transfer to ICU (50.3% Vs 22.8%, respectively; p < 0.001). However, a similar proportion of subjects needed admission to socio-health centers or transfer to their regional hospital for convalescence. Six patients of the ICU group were still hospitalized, while none of the IMCU subjects were in the hospital at the end of follow-up. A comparison of clinical outcomes between groups is presented in Table 2.
Table 2
Clinical outcomes of all patients admitted to the respiratory intermediate care unit, and according to requirement of transfer to the ICU

|                                | Total (N = 253) | No ICU admission (N = 161) | ICU admission (N = 92) | p-value |
|--------------------------------|-----------------|---------------------------|-----------------------|---------|
| Home discharge, n (%)          | 102 (40.3%)     | 81 (50.3%)                | 21 (22.8%)            | < 0.001*|
| Socio-health center transfer, n (%) | 65 (25.7%)     | 41 (25.5%)                | 24 (26.1%)            | > 0.999 |
| Ongoing hospitalization, n (%) | 6 (2.4%)        | 0                         | 6 (6.5%)              | 0.002*  |
| Deaths during admission, n (%) | 80 (31.6%)      | 39 (24.2%)                | 41 (44.6%)            | 0.001*  |
| Length of IMCU stay in days, median (IQR) | 6 (7)           | 7 (6)                     | 4 (5.3)               | < 0.001*|
| Length of hospital stay in days, median (IQR) | 15 (17)        | 13 (9)                    | 30 (31.3)             | < 0.001*|

IQR: Interquartile range; ICU: Intensive care unit; IMCU: Intermediate care unit

Mortality

Eighty patients (31.6%) died during hospitalization. Main causes of death were ARDS and septic shock. Patients requiring transfer to the ICU had a higher mortality rate (44.6% Vs 24.2%; p < 0.001). When comparing survivors and non-survivors, a significant difference was observed regarding age (median 61 years, IQR 17 V s median 72 years, IQR 10.3, respectively; p < 0.001). Non-survivors had a higher proportion of comorbidities such as dyslipidemia, chronic respiratory diseases and chronic kidney disease. Furthermore, these patients had higher blood leukocyte counts, serum lactate dehydrogenase (LDH), C-reactive protein and D-dimer, and lower blood lymphocyte counts on admission to the IMCU (Table 3).
Table 3

Patient characteristics regarding in-hospital mortality

|                                      | Survivors (N=173) | Non-survivors (N=80) | p-value |
|--------------------------------------|-------------------|-----------------------|---------|
| Male, n (%)                          | 121 (69.9%)       | 51 (63.8%)            | 0.403   |
| Age, median (IQR)                    | 61 (17)           | 72 (10.3)             | <0.001* |
| **Comorbidities**                    |                   |                       |         |
| Hypertension, n (%)                  | 83 (47.9%)        | 44 (55%)              | 0.366   |
| Diabetes, n (%)                      | 49 (28.3%)        | 26 (32.5%)            | 0.597   |
| Dyslipidemia, n (%)                  | 73 (42.2%)        | 48 (60%)              | 0.012*  |
| Obesity, n (%)                       | 46 (26.6%)        | 17 (21.3%)            | 0.449   |
| Cardiovascular disease, n (%)        | 16 (9.3%)         | 11 (13.8%)            | 0.390   |
| Chronic respiratory disease, n (%)   |                   |                       |         |
| Asthma                               | 8 (4.6%)          | 6 (7.5%)              | 0.008*  |
| COPD                                 | 8 (4.6%)          | 9 (11.3%)             |         |
| Interstitial lung disease            | 1 (0.6%)          | 5 (6.3%)              |         |
| Bronchiectasis                       | 1 (0.6%)          | 0                     |         |
| OSAS                                 | 9 (5.2%)          | 6 (7.5%)              |         |
| History of malignancy, n (%)         | 20 (11.6%)        | 17 (21.3%)            | 0.066   |
| Hepatopathy, n (%)                   | 19 (10.9%)        | 3 (3.8%)              | 0.097   |
| Chronic kidney disease, n (%)        | 11 (6.4%)         | 16 (20%)              | 0.002*  |
| Immunosuppression, n (%)             | 6 (3.5%)          | 7 (8.8%)              | 0.121   |
| **Symptoms**                         |                   |                       |         |
| Dyspnea, n (%)                       | 103 (59.5%)       | 46 (57.5%)            | 0.866   |
| Cough, n (%)                         | 134 (77.5%)       | 55 (68.8%)            | 0.185   |
| Fever, n (%)                         | 149 (86.1%)       | 62 (77.5%)            | 0.125   |
| Myalgias, n (%)                      | 53 (30.6%)        | 18 (22.5%)            | 0.235   |
| Diarrhea, n (%)                      | 45 (26%)          | 19 (23.8%)            | 0.819   |
| Nausea, n (%)                        | 14 (8.1%)         | 8 (10%)               | 0.794   |
| Days from symptom onset to hospital admission, | 8 (5)         | 8 (4.8)               | 0.457   |
| Days from symptom onset to IMCU admission, median (IQR) | 10 (7) | 10 (7) | 0.745 |
|--------------------------------------------------------|--------|--------|--------|
| **Chest X-ray on admission**                           |        |        |        |
| Bilateral opacities, n (%)                             | 158 (92.9%) | 74 (92.5%) | >0.999 |
| Peripheral distribution, n (%)                         | 105 (61.8%) | 39 (48.8%) | 0.071 |
| **Laboratory blood tests**                             |        |        |        |
| Leukocyte count (x10^9/L), median (IQR)                | 8.20 (5.2) | 10.20 (5.7) | <0.001* |
| Lymphocyte count (x10^9/L), median (IQR)               | 0.75 (0.6) | 0.52 (0.5) | <0.001* |
| Lactate dehydrogenase (U/L), median (IQR)              | 395 (184.3) | 476 (251) | <0.001* |
| C-Reactive protein (mg/L), median (IQR)                | 108 (167) | 169 (196.5) | <0.001* |
| Ferritin (µg/L), median (IQR)                          | 1369 (1213.5) | 1792 (1444) | 0.128 |
| D-dimer (µg/L), median (IQR)                           | 432 (784) | 701 (1756) | <0.001* |
| **Treatment**                                          |        |        |        |
| Lopinavir/Ritonavir, n (%)                             | 134 (77.5%) | 68 (85%) | 0.222 |
| Remdesivir, n (%)                                      | 9 (5.2%) | 2 (2.5%) | 0.510 |
| Hydroxychloroquine, n (%)                              | 164 (94.8%) | 79 (98.8%) | 0.177 |
| Tocilizumab, n (%)                                     | 83 (47.9%) | 41 (51.3%) | 0.727 |
| Systemic corticosteroids, n (%)                        |        |        |        |
| Intravenous bolus                                      | 70 (40.5%) | 44 (55%) | 0.002* |
| Intravenous bolus + oral tapering regimen              | 46 (26.6%) | 6 (7.5%) |        |
| Oral tapering regimen                                  | 3 (1.7%) | 1 (1.3%) |        |
| **SpO2/FiO2 ratio, median (IQR)**                      | 137.10 (82.2) | 123.39 (37.4) | <0.001* |
| **Respiratory support**                                |        |        |        |
| High-flow oxygen, n (%)                                | 110 (63.6%) | 55 (68.8%) | 0.509 |
| Non-invasive ventilation, n (%)                        | 64 (36.9%) | 69 (86.3%) | <0.001* |
| Invasive mechanical ventilation, n (%)                 | 42 (24.3%) | 40 (50%) | <0.001* |
| Tracheostomy, n (%)                                    | 18 (10.4%) | 11 (13.8%) | 0.572 |
| **Transfer to ICU, n (%)**                             | 51 (29.5%) | 41 (51.3%) | 0.001* |
| Length of IMCU stay in days, median (IQR) | 7 (8) | 4 (5) | <0.001* |
| Length of hospital stay in days, median (IQR) | 17 (19) | 12 (14.5) | <0.001* |

IQR: Interquartile range; COPD: Chronic obstructive pulmonary disease; OSAS: Obstructive sleep apnea syndrome; SpO2: Oxygen saturation; FiO2: Fraction of inspired oxygen; IMCU: Intermediate care unit; ICU: Intensive care unit.

We compared groups of deceased patients. Subjects who died at the IMCU were significantly older (median 76 years, IQR 4.5 vs. median 66 years, IQR 12; p < 0.001). Nevertheless, similar proportions of gender, comorbidities and laboratory findings on admission were observed between groups.

**Survival analysis**

Kaplan-Meier survival analysis identified a significant higher mortality in patients of 65 years of age or older (Fig. 1). Also, significant differences in survival time were observed regarding chronic respiratory and renal conditions and corticosteroid treatment during hospitalization (Fig. 2).

Variables that independently increased risk of death in the multivariable Cox proportional hazards analysis included: age equal or older than 65 years (hazard ratio [HR] 4.14; 95% confidence interval [CI] 2.31–7.42; p < 0.001); chronic respiratory conditions (HR 2.34; 95% CI 1.38–3.99; p = 0.002) and chronic kidney disease (HR 2.96; 95% CI 1.61–5.43; p < 0.001). Patients receiving high dose systemic corticosteroids followed by or progressive dose tapering showed a significant lower risk of death (HR 0.15; 95% CI 0.06–0.40; p < 0.001). Regarding laboratory findings on admission, blood leukocyte counts higher than $10 \times 10^9$/L and lymphocyte counts lower than $0.4 \times 10^9$/L were associated with higher risk of death (HR 2.19; 95% CI 1.30–3.71; p = 0.003 and HR 2.05; 95% CI 1.19–3.53; p = 0.010). Furthermore, serum LDH higher than 445 U/L was also independently associated with mortality (HR 1.83; 95% CI 1.04–3.21; p = 0.035). Figure 3 shows the results for the multivariable Cox proportional hazards model.

**Discussion**

This is one of the first and largest studies to assess the impact of IMCU during COVID-19 pandemic. The IMCU allows a secure environment for providing non-invasive respiratory support and patient monitoring, leading to positive patient outcomes and improving healthcare resource management.

Patient characteristics and clinical presentation of the disease are similar to what has been described in previous studies (7, 18–20). Our cohort includes a large number of patients with severe respiratory failure, determined by a median SpO2/FiO2 ratio of 132.90. These patients may have required admission to ICU in hospitals without IMCU, possibly leading to further ICU collapse. To this date, there is limited data addressing the specific role of IMCU as a way of reducing the ICU transfer rate of severe COVID-19 patients. A study by Lagi et al. showed that improving nurse/patient ratio to 1:6 and using HFNC on regular wards resulted in a 12% reduction of ICU transfer (21). In this regard, our hospital rapidly
increased the number of IMCU beds due to the pandemic situation, maintaining a nurse/patient ratio of 1:4 and non-invasive monitoring. In our cohort, only 36% of patients admitted to an IMCU required upscaling management to the ICU. This resulted in a reduction of ICU burden and allowed for more response time to face the rapid increase of severe cases. A previous study by Heili-Frades et al. showed that IMCU may avoid approximately 500,000 euros per year of hospital costs, especially in high complexity patients requiring HFNC oxygen therapy or NIV (8). Although the specific admission costs of COVID-19 patients have not been estimated, the IMCU not only could help to improve ICU bed availability, but also to lower overall healthcare costs.

All-cause mortality in our cohort was 31.6%, similar to what has been observed in other cohorts. A recent study by Li et al. showed that mortality in severe cases was 32.5% during the 32 days follow-up period, regardless of respiratory support requirement (18). Also, two cohorts of patients admitted to critical care (ICU or IMCU), one from UK and the other from Italy, reported a similar mortality rate (14). A multicenter European cohort study demonstrated that the availability of IMCU significantly reduced adjusted hospital mortality for adults admitted to the ICU (11). However, data is scarce regarding the impact of IMCU on mortality of severe COVID-19 patients. In this regard, Franco et al. observed that the implementation of non-invasive respiratory support outside the ICU had favorable results, with an overall mortality rate of 26.9% (22). Similarly, we observed that mortality in IMCU patients who did not require ICU admission was 24.2%, significantly lower than in the ICU group. This may be expected, as most of the patients in the ICU group were more severely ill and required invasive mechanical ventilation.

Survival analysis showed significant differences between patients of 65 years of age or older, and in those with chronic renal and respiratory diseases. These conditions were identified as independent risk factors for in-hospital mortality. Older age has been associated with an increase in the risk of death in several previous studies (18–20, 23). However, few of the published multivariable models for mortality risk in COVID-19 patients include chronic respiratory and renal diseases. Our results are in agreement with recent observations showing that patients with chronic obstructive pulmonary disease, interstitial lung diseases or chronic kidney disease that require hospitalization because of COVID-19 have higher risk of death (7, 20, 24). While the overall in-hospital mortality rate of interstitial lung disease (ILD) patients was 49% in the ISARIC4C study (24), the mortality rate of those ILD patients in our IMCU cohort was 83.3%, which suggests that the requirement of high-flux or non-invasive mechanical ventilation in ILD patients with severe COVID-19 associates a poor prognosis. Regarding laboratory findings, our model results show similarities with observations from prior cohorts, where patients with leukocytosis, lymphopenia and elevated serum LDH on admission have a higher mortality risk (4, 18, 19, 23).

Concerning patient treatment, only systemic corticosteroids were independently associated with a reduction of mortality in our cohort. Subjects receiving 3 days of high-dose methylprednisolone or dexamethasone followed by 7 days of oral dose tapering had a lower risk of death than those who received shorter treatments or were not treated. The positive effect of systemic corticosteroids has been described in recent studies. In a cohort from Wuhan, patients treated with methylprednisolone had a lower mortality rate (23). Also, a preliminary report of the RECOVERY trial showed that patients receiving
Dexamethasone for up to 10 days resulted in lower all-cause mortality (15). Furthermore, a recent meta-analysis by the World Health Organization Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group concluded that the administration of systemic corticosteroids in critically-ill COVID-19 patients was associated with a lower 28-day mortality, compared to usual care or placebo (25). Nevertheless, though the beneficial effect is clear in severe cases, the optimal dose and dose-reduction should be better evaluated for avoiding adverse events at the same time than achieving a proper lung recovery.

This study has several limitations, mainly related to the retrospective design of the analysis including a single center. The lack of a control group (non-IMCU hospital) does not allow to directly quantify the impact of IMCU in COVID-19 mortality or health-care burden. Also, our cohort included only severe patients, as we focused on the role of IMCU in patient management. This may limit the generalization of our results to less severe cases. Also, local treatment protocols changed during the inclusion period due to the pandemic situation and the scarce data on COVID-19, which may have influenced the clinical outcomes of our study. However, the number of participants is higher than most previous studies, and our results agree with observations from different cohorts.

**Conclusions**

IMCU allow to safely and effectively manage severe COVID-19 patients requiring non-invasive respiratory support and monitoring, therefore reducing ICU burden. Older age and chronic respiratory or renal conditions are associated with worse clinical outcomes while treatment with systemic corticosteroids may have a protective effect on mortality.

**Abbreviations**

ARDS: Acute respiratory distress syndrome

COVID-19: Coronavirus disease 2019

FiO2: Inspired oxygen fraction

HFNC: High-flow nasal cannula

ICU: Intensive care unit

ILD: Interstitial lung disease

IMCU: Intermediate respiratory care unit

LDH: Lactate dehydrogenase

NIV: Non-invasive ventilation
SARS-CoV-2: Severe acute respiratory syndrome-coronavirus-2

SpO2: Oxygen saturation

Declarations

Ethics approval and consent to participate:

Study protocol was approved by the ethics committee of Bellvitge University Hospital (Nº PR260/20). All subjects gave their informed consent to participate in this study.

Consent for publication:

Not applicable.

Availability of data and materials:

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests:

GSC reports grants from Grifols. MMM reports grants from Boehringer Ingelheim, Roche, Glaxo-Smith-Kline, Esteve-Teijin, Almirall and Chiesi outside the submitted work. All other authors declare that they have no competing interests.

Funding:

This study received funding from Linde Healthcare and Menarini. Funding bodies did not participate in the design of the study or in the collection, analysis, and interpretation of data.

Authors' contributions:

GSC participated in study design, acquisition, analysis, and interpretation of data, and in the elaboration of the manuscript. MG participated in study design, acquisition, analysis, and interpretation of data, and in the elaboration of the manuscript. GB participated in data acquisition and in the elaboration of the manuscript. YRA participated in data acquisition, analysis, and interpretation of data. MHA participated in data acquisition and analysis. AM participated in data acquisition and analysis. PTS participated in data acquisition and analysis. AC participated in data acquisition and analysis. AA participated in data
acquisition and analysis. JS participated in data acquisition, analysis and interpretation of the results. NR participated in data acquisition and analysis. CS participated in data acquisition and analysis. MMM participated in study design, interpretation of data, and in the elaboration of the manuscript. SS participated in study design, interpretation of data and in the elaboration of the manuscript. All authors read and approved the final manuscript.

Acknowledgements:

The authors acknowledge all health-care workers involved in patient management for their hard work and dedication.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.

2. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun 1;20(6):669–77.

3. Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, Egea Santaolalla C, Masa Jiménez JF, García Fernández J, et al. Clinical Consensus Recommendations Regarding Non-Invasive Respiratory Support in the Adult Patient with Acute Respiratory Failure Secondary to SARS-CoV-2 infection. Arch Bronconeumol. 2020 Jul 1;

4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020 Mar 17;323(11):1061–9.

6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.

7. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.

8. Heili Frades S, Carballosa de Miguel M del P, Naya Prieto A, Galdeano Lozano M, Mate García X, Mahillo Fernández I, et al. Cost and Mortality Analysis of an Intermediate Respiratory Care Unit. Is It Really Efficient and Safe? Arch Bronconeumol (English Ed. 2019 Dec 1;55(12):634–41.

9. Prin M, Wunsch H. The role of stepdown beds in hospital care. Am J Respir Crit Care Med. 2014 Dec 1;190(11):1210–6.
10. Plate JDJ, Leenen LPH, Houwert M, Hietbrink F. Utilisation of Intermediate Care Units: A Systematic Review. Crit Care Res Pract. 2017;2017:8038460.

11. Capuzzo M, Volta CA, Tassinati T, Moreno RP, Valentin A, Guidet B, et al. Hospital mortality of adults admitted to intensive care units in hospitals with and without intermediate care units: A multicentre European cohort study. Crit Care. 2014 Oct 9;18(5):551.

12. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of 11 August 2020 [Internet]. [cited 2020 Aug 11]. Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases

13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507–13.

14. Grasselli G, Zanigrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA - J Am Med Assoc. 2020 Apr 28;323(16):1574–81.

15. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med. 2020 Jul 17;Online ahead of print.

16. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007 Aug;132(2):410–7.

17. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–20.

18. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Jul 1;146(1):110–8.

19. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: A prospective cohort study. Eur Respir J. 2020 May 1;55(5).

20. Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020 Jun 22;Online ahead of print.

21. Lagi F, Piccica M, Graziani L, Vellere I, Botta A, Tilli M, et al. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020. Eurosurveillance. 2020 Apr 30;25(17):2000556.

22. Franco C, Facciolongo N, Tonelli R, Dongilli R, Vianello A, Pisani L, et al. Feasibility and clinical impact of out-of-ICU non-invasive respiratory support in patients with COVID-19 related pneumonia. Eur Respir J. 2020 Aug 3;2002130:Online ahead of print.

23. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934–43.
24. Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study. Am J Respir Crit Care Med. 2020 Oct 2;Online ahead of print.

25. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz J V, Slutsky AS, Villar J, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;Online ahead of print.

**Figures**

**Figure 1**

Kaplan-Meier survival analysis by age and previous chronic respiratory conditions.
Figure 1

Kaplan-Meier survival analysis by age and previous chronic respiratory conditions.
Figure 2

Kaplan-Meier survival analysis by previous chronic renal disease and systemic corticosteroid treatment.
Figure 3

Multivariable Cox proportional hazards model for the assessment of in-hospital death risk.
Figure 3

Multivariable Cox proportional hazards model for the assessment of in-hospital death risk.